GJEL Office Locations:

Zyprexa News Release

Pharmaceutical giant Eli Lilly & Company has agreed to pay $700 million to members of a product liability group settlement, ending a six-month negotiation between the company and attorneys representing approximately 8,000 affected users of the anti-depressant drug Zyprexa (Olanzapine). At least 23 deaths have been associated with Zyprexa use to date.

A team of attorneys from across the country, including Gillin, Jacobson, Ellis & Larsen, joined forces in the effort against Eli Lilly & Company. Zyprexa, manufactured by Lilly, is an anti-depressant drug that has been associated with a 37% increase in the risk of diabetes or hypoglycemia-related diseases when compared to other atypical anti-psychotic medications. GJEL represents approximately 100 persons who suffered damages as a result of taking the drug.

In September 2003, the FDA asked Eli Lilly to add a warning about the risk of diabetes and other hypoglycemia-related diseases on labels for Zyprexa. Nations such as Japan and the U.K. have required warnings concerning Zyprexa and diabetes for many years.

Zyprexa received FDA approval for the treatment of schizophrenia in September, 1996. Since that time, Zyprexa has been approved for treatment of acute bipolar mania and is regularly prescribed for mental disorders ranging from schizophrenia, dementia, autism, aggressive behavior, personality disorders, post-traumatic stress disorder to severe depression. Many of these conditions are common and require life-long treatment.